US Patent 7652044 P-38 inhibitors
Patent 7652044 was granted and assigned to Novartis on January, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+451 characters)
Article
Patent abstract
Provided are 5-membered heterocycle-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07652044 P-38 inhibitors US Patent 7652044 P-38 inhibitors
Infobox
Patent Number
0765204400
Patent Number
765204400
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 29 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076520440
Date of Patent
January 26, 2010
0Patent Application Number
108607680
Date Filed
June 2, 2004
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076520440
Date of Patent
January 26, 2010
0Patent Application Number
108607680
Date Filed
June 2, 2004
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07652044 P-38 inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07652044
Date of patent
January 26, 2010
Patent application number
10860768
Date Filed
June 2, 2004
Patent primary examiner
Find more entities like US Patent 7652044 P-38 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
